Advanced search
Publication Cover
OncoImmunology Volume 7, 2018 - Issue 2
Submit an article Journal homepage
3,956
Views
53
CrossRef citations to date
0
Altmetric
Brief Report

CD20-selective inhibition of CD47-SIRPα “don't eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab

Peter E. van BommelUniversity of Groningen, University Medical Center Groningen (UMCG), Department of Surgery, Laboratory for Translational Surgical Oncology, Groningen, The Netherlands
,
Yuan HeUniversity of Groningen, University Medical Center Groningen (UMCG), Department of Hematology, Groningen, The Netherlands
,
Ilona SchepelUniversity of Groningen, University Medical Center Groningen (UMCG), Department of Surgery, Laboratory for Translational Surgical Oncology, Groningen, The Netherlands
,
Mark A. J. M. HendriksUniversity of Groningen, University Medical Center Groningen (UMCG), Department of Surgery, Laboratory for Translational Surgical Oncology, Groningen, The Netherlands
,
Valerie R. WiersmaUniversity of Groningen, University Medical Center Groningen (UMCG), Department of Surgery, Laboratory for Translational Surgical Oncology, Groningen, The Netherlands
,
Robert J. van GinkelUniversity of Groningen, University Medical Center Groningen (UMCG), Department of Surgery, Laboratory for Translational Surgical Oncology, Groningen, The Netherlands
,
Tom van MeertenUniversity of Groningen, University Medical Center Groningen (UMCG), Department of Hematology, Groningen, The Netherlands
,
Emanuele AmmatunaUniversity of Groningen, University Medical Center Groningen (UMCG), Department of Hematology, Groningen, The Netherlands
,
Gerwin HulsUniversity of Groningen, University Medical Center Groningen (UMCG), Department of Hematology, Groningen, The Netherlands
,
Douwe F. SamploniusUniversity of Groningen, University Medical Center Groningen (UMCG), Department of Surgery, Laboratory for Translational Surgical Oncology, Groningen, The Netherlands
,
Wijnand HelfrichUniversity of Groningen, University Medical Center Groningen (UMCG), Department of Surgery, Laboratory for Translational Surgical Oncology, Groningen, The NetherlandsCorrespondence[email protected]
&
Edwin BremerUniversity of Groningen, University Medical Center Groningen (UMCG), Department of Hematology, Groningen, The NetherlandsCorrespondence[email protected]
 show all
Article: e1386361 | Received 02 Aug 2017, Accepted 24 Sep 2017, Published online: 31 Oct 2017

Citations (53)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

Maxime Jullien, Cyrille Touzeau & Philippe Moreau. (2021) Monoclonal antibodies as an addition to current myeloma therapy strategies. Expert Review of Anticancer Therapy 21:1, pages 33-43.
Read now
Mark A. J. M. Hendriks, Emily M. Ploeg, Iris Koopmans, Isabel Britsch, Xiurong Ke, Douwe F. Samplonius & Wijnand Helfrich. (2020) Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα “don’t eat me” immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation. OncoImmunology 9:1.
Read now
Isaure Vanmeerbeek, Jenny Sprooten, Dirk De Ruysscher, Sabine Tejpar, Peter Vandenberghe, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi & Abhishek D. Garg. (2020) Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. OncoImmunology 9:1.
Read now
Nicola Giuliani, Fabrizio Accardi, Valentina Marchica, Benedetta Dalla Palma, Paola Storti, Denise Toscani, Emanuela Vicario & Fabio Malavasi. (2019) Novel targets for the treatment of relapsing multiple myeloma. Expert Review of Hematology 12:7, pages 481-496.
Read now
Laahn H. Foster & Lawrence G. Lum. (2019) Treatment of hematological malignancies with T cell redirected bispecific antibodies: current status and future needs. Expert Opinion on Biological Therapy 19:7, pages 707-720.
Read now
Francesca Bonello, Mattia D’Agostino, Maria Moscvin, Chiara Cerrato, Mario Boccadoro & Francesca Gay. (2018) CD38 as an immunotherapeutic target in multiple myeloma. Expert Opinion on Biological Therapy 18:12, pages 1209-1221.
Read now

Articles from other publishers (47)

Chao Wang, Ying Feng, Deepali Patel, Hongwei Xie, Yaqing Lv & Hai Zhao. (2023) The role of CD47 in non-neoplastic diseases. Heliyon 9:12, pages e22905.
Crossref
Ming Li, Mengjie Wang, Yuanjia Wen, Hongfei Zhang, Guang‐Nian Zhao & Qinglei Gao. (2023) Signaling pathways in macrophages: molecular mechanisms and therapeutic targets. MedComm 4:5.
Crossref
Emily Maria Ploeg, Isabel Britsch, Anne Paulien van Wijngaarden, Xiurong Ke, Mark Alexander Johannes Martinus Hendriks, Douwe Freerk Samplonius & Wijnand Helfrich. (2023) A Novel Bispecific Antibody for EpCAM-Directed Inhibition of the CD73/Adenosine Immune Checkpoint in Ovarian Cancer. Cancers 15:14, pages 3651.
Crossref
Yu Hao, Xinxuan Zhou, Yiling Li, Bolei Li & Lei Cheng. (2023) The CD47-SIRPα axis is a promising target for cancer immunotherapies. International Immunopharmacology 120, pages 110255.
Crossref
Paul Chaintreuil, Emeline Kerreneur, Maxence Bourgoin, Coline Savy, Cécile Favreau, Guillaume Robert, Arnaud Jacquel & Patrick Auberger. (2023) The generation, activation, and polarization of monocyte-derived macrophages in human malignancies. Frontiers in Immunology 14.
Crossref
Zi-Han Ye, Wei-Bang Yu, Mu-Yang Huang, Jun Chen & Jin-Jian Lu. (2023) Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives. Acta Pharmaceutica Sinica B 13:4, pages 1467-1487.
Crossref
Jifeng Yu, Song Li, Dianze Chen, Dandan Liu, Huiqin Guo, Chunmei Yang, Wei Zhang, Li Zhang, Gui Zhao, Xiaoping Tu, Liang Peng, Sijin Liu, Xing Bai, Yongping Song, Zhongxing Jiang, Ruliang Zhang & Wenzhi Tian. (2022) IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPα interaction and FcɣR engagement by simultaneously binding to CD47 and CD20 of B cells. Leukemia 37:3, pages 695-698.
Crossref
Danilo De Novellis, Raffaele Fontana, Valentina Giudice, Bianca Serio & Carmine Selleri. (2022) Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance. International Journal of Molecular Sciences 24:1, pages 645.
Crossref
Alberto Mantovani, Paola Allavena, Federica Marchesi & Cecilia Garlanda. (2022) Macrophages as tools and targets in cancer therapy. Nature Reviews Drug Discovery 21:11, pages 799-820.
Crossref
Binglei Zhang, Wei Li, Dandan Fan, Wenzhi Tian, Jian Zhou, Zhenyu Ji & Yongping Song. (2022) Advances in the study of CD47 ‐based bispecific antibody in cancer immunotherapy . Immunology 167:1, pages 15-27.
Crossref
Wei Li, Fang Wang, Rongqun Guo, Zhilei Bian & Yongping Song. (2022) Targeting macrophages in hematological malignancies: recent advances and future directions. Journal of Hematology & Oncology 15:1.
Crossref
Renée Bouwstra, Tom van Meerten & Edwin Bremer. (2022) CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies. Clinical and Translational Medicine 12:8.
Crossref
Sotirios G. Papageorgiou, Thomas P. Thomopoulos, Athanasios Liaskas & Theodoros P. Vassilakopoulos. (2022) Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab. Cancers 14:8, pages 1917.
Crossref
Susan Moradinasab, Atieh Pourbagheri-Sigaroodi, Seyed H. Ghaffari & Davood Bashash. (2022) Targeting macrophage-mediated tumor cell phagocytosis: An overview of phagocytosis checkpoints blockade, nanomedicine intervention, and engineered CAR-macrophage therapy. International Immunopharmacology 103, pages 108499.
Crossref
Yehong Tan, Hanhua Chen, Jie Zhang, Linxiang Cai, Suxing Jin, Dongfan Song, Tao Yang, Zijian Guo & Xiaoyong Wang. (2022) Platinum(IV) complexes as inhibitors of CD47-SIRPα axis for chemoimmunotherapy of cancer. European Journal of Medicinal Chemistry 229, pages 114047.
Crossref
Fei Shen & Weidong Shen. (2022) Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab. Technology in Cancer Research & Treatment 21, pages 153303382211065.
Crossref
Kristine A. FrerichsMonique C. Minnema, Mark-David LevinAnnemiek BroijlGerard M. J. BosMarie José KerstenTuna MutisChristie P. M. Verkleij, Inger S. NijhofPatricia W. C. Maas-BosmanSaskia K. Klein, Sonja ZweegmanPieter SonneveldNiels W. C. J. van de Donk. (2021) Efficacy and safety of daratumumab combined with all- trans retinoic acid in relapsed/refractory multiple myeloma . Blood Advances 5:23, pages 5128-5139.
Crossref
Emily M. Ploeg, Xiurong Ke, Isabel Britsch, Mark A.J.M. Hendriks, Femke A. Van der Zant, Schelto Kruijff, Douwe F. Samplonius, Hao Zhang & Wijnand Helfrich. (2021) Bispecific antibody CD73xEpCAM selectively inhibits the adenosine-mediated immunosuppressive activity of carcinoma-derived extracellular vesicles. Cancer Letters 521, pages 109-118.
Crossref
Sushanth Gouni, Mario L. Marques-Piubelli & Paolo Strati. (2021) Follicular lymphoma and macrophages: impact of approved and novel therapies. Blood Advances 5:20, pages 4303-4312.
Crossref
Walter Ferlin, Krzysztof Masternak & Limin Shang. (2021) Selective CD47 targeting with a bispecific antibody. Cancer Immunology, Immunotherapy 70:4, pages 1161-1162.
Crossref
Hend Mohamed Abdel‐Bar, Adam A. Walters, Julie Tzu‐Wen Wang & Khuloud T. Al‐Jamal. (2021) Combinatory Delivery of Etoposide and siCD47 in a Lipid Polymer Hybrid Delays Lung Tumor Growth in an Experimental Melanoma Lung Metastatic Model. Advanced Healthcare Materials 10:7.
Crossref
Siqi Chen, Seigmund W. T. Lai, Christine E. Brown & Mingye Feng. (2021) Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy. Frontiers in Immunology 12.
Crossref
Anthony Brouillard, Nilesh Deshpande & Ashish A. Kulkarni. (2021) Engineered Multifunctional Nano‐ and Biological Materials for Cancer Immunotherapy. Advanced Healthcare Materials 10:6.
Crossref
Jennifer Sun, Yixuan Chen, Berit Lubben, Ola Adebayo, Barbara Muz & Abdel Kareem Azab. (2021) CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies. Leukemia Research Reports 16, pages 100268.
Crossref
Yongheng Shu & Ping Cheng. (2020) Targeting tumor-associated macrophages for cancer immunotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1874:2, pages 188434.
Crossref
Natasha Ustyanovska Avtenyuk, Nienke Visser, Edwin Bremer & Valerie R. Wiersma. (2020) The Neutrophil: The Underdog That Packs a Punch in the Fight against Cancer. International Journal of Molecular Sciences 21:21, pages 7820.
Crossref
Hongfei Wang, Yixuan Sun, Xiuman Zhou, Chunxia Chen, Ling Jiao, Wanqiong Li, Shanshan Gou, Yanying Li, Jiangfeng Du, Guanyu Chen, Wenjie Zhai, Yahong Wu, Yuanming Qi & Yanfeng Gao. (2020) CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy. Journal for ImmunoTherapy of Cancer 8:2, pages e000905.
Crossref
Christoph Rader. (2020) Bispecific antibodies in cancer immunotherapy. Current Opinion in Biotechnology 65, pages 9-16.
Crossref
Paola Storti, Federica Costa, Valentina Marchica, Jessica Burroughs-Garcia, Benedetta dalla Palma, Denise Toscani, Rosa Alba Eufemiese & Nicola Giuliani. (2020) Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies. Journal of Clinical Medicine 9:9, pages 2864.
Crossref
Ankur Jain & Karthik Ramasamy. (2020) Evolving Role of Daratumumab: From Backbencher to Frontline Agent. Clinical Lymphoma Myeloma and Leukemia 20:9, pages 572-587.
Crossref
Paola Storti, Rosanna Vescovini, Federica Costa, Valentina Marchica, Denise Toscani, Benedetta Dalla Palma, Luisa Craviotto, Fabio Malavasi & Nicola Giuliani. (2020) CD14 + CD16 + monocytes are involved in daratumumab‐mediated myeloma cells killing and in anti‐CD47 therapeutic strategy . British Journal of Haematology 190:3, pages 430-436.
Crossref
Sung In Lim. (2020) Fine-tuning bispecific therapeutics. Pharmacology & Therapeutics 212, pages 107582.
Crossref
Sukhbir Kaur, Kyle V Cicalese, Rajdeep Banerjee & David D Roberts. (2020) Preclinical and clinical development of therapeutic antibodies targeting functions of CD47 in the tumor microenvironment. Antibody Therapeutics 3:3, pages 179-192.
Crossref
Margaux Lejeune, Murat Cem Köse, Elodie Duray, Hermann Einsele, Yves Beguin & Jo Caers. (2020) Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies. Frontiers in Immunology 11.
Crossref
Laurens E. Franssen, Claudia A. M. Stege, Sonja Zweegman, Niels W. C. J. van de Donk & Inger S. Nijhof. (2020) Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma. Journal of Clinical Medicine 9:4, pages 1195.
Crossref
Ilaria Saltarella, Vanessa Desantis, Assunta Melaccio, Antonio Giovanni Solimando, Aurelia Lamanuzzi, Roberto Ria, Clelia Tiziana Storlazzi, Maria Addolorata Mariggiò, Angelo Vacca & Maria Antonia Frassanito. (2020) Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma. Cells 9:1, pages 167.
Crossref
Maximilian Johannes Steinhardt, Xiang Zhou, Franziska Krummenast, Katharina Meckel, Katharina Nickel, David Böckle, Janin Messerschmidt, Sebastian Knorz, Alexander Dierks, Anke Heidemeier, Constantin Lapa, Hermann Einsele, Leo Rasche & Klaus Martin Kortüm. (2020) Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma. International Journal of Immunopathology and Pharmacology 34, pages 205873842098025.
Crossref
Jérôme Moreaux. (2020) Anticorps anti-CD38 dans le myélome multiple. médecine/sciences 35:12, pages 1001-1004.
Crossref
Raoufeh Ahamadi-Fesharaki, Abolfazl Fateh, Farzam Vaziri, Ghasem Solgi, Seyed Davar Siadat, Fereidoun Mahboudi & Fatemeh Rahimi-Jamnani. (2019) Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow. Molecular Therapy - Oncolytics 14, pages 38-56.
Crossref
Niels W.C.J. van de Donk. (2019) Reprint of “Immunomodulatory effects of CD38-targeting antibodies”. Immunology Letters 205, pages 71-77.
Crossref
Yuan He, Wijnand Helfrich & Edwin Bremer. 2019. Cancer Immunosurveillance. Cancer Immunosurveillance 335 347 .
Jin Zhang, Shenhe Jin, Xiaojun Guo & Wenbin Qian. (2018) Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy. Journal of International Medical Research 46:11, pages 4418-4426.
Crossref
Niels W.C.J. van de Donk & Saad Z. Usmani. (2018) CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance. Frontiers in Immunology 9.
Crossref
Bing Tong & Mengzhao Wang. (2018) CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises. Future Oncology 14:21, pages 2179-2188.
Crossref
Niels W.C.J. van de Donk. (2018) Immunomodulatory effects of CD38-targeting antibodies. Immunology Letters 199, pages 16-22.
Crossref
Jacob P. LaubachNiels van de DonkFaith E. DaviesJoseph Mikhael. (2018) Practical Considerations for Antibodies in Myeloma. American Society of Clinical Oncology Educational Book:38, pages 667-674.
Crossref
Elie Dheilly, Stefano Majocchi, Valéry Moine, Gérard Didelot, Lucile Broyer, Sébastien Calloud, Pauline Malinge, Laurence Chatel, Walter Ferlin, Marie Kosco-Vilbois, Nicolas Fischer & Krzysztof Masternak. (2018) Tumor-Directed Blockade of CD47 with Bispecific Antibodies Induces Adaptive Antitumor Immunity. Antibodies 7:1, pages 3.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.